105 Quick summary: Advanced laboratory research published in April 2026 demonstrates that a modified form of vitamin B12 known as nitrosylcobalamin can successfully cross the blood brain barrier to selectively target and accumulate within glioblastoma tumour tissue. Animal experiments and cell analyses reveal that this natural compound analog significantly enhances the suppression of cancer cell proliferation when combined with existing chemotherapies, working independently to bypass traditional drug resistance mechanisms. These pioneering oncological findings carry profound implications for healthcare practice and public policy, offering a highly precise drug delivery framework that could dramatically extend median survival rates and improve the therapeutic well being of patients battling aggressive brain malignancies. A modified form of vitamin B12 has shown promise as a potential treatment for glioblastoma, one of the most aggressive and deadly forms of brain cancer, according to new laboratory research. The study, published in Volume 13 of Oncoscience on 2nd April 2026, is titled “Selective blood–brain barrier penetration and tumour targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with TRAIL and temozolomide.” It was led by first and corresponding author Joseph A. Bauer affiliated with Nitric Oxide Services, LLC, and the Cleveland Clinic Foundation Taussig Cancer Center Glioblastoma multiforme remains 1 of the most treatment-resistant brain cancers, with median survival typically under 15 months despite surgery, radiation, and chemotherapy. A major obstacle is the blood-brain barrier, a protective shield that prevents many anticancer drugs from reaching tumour tissue effectively. Researchers investigated whether nitrosylcobalamin, a nitric oxide-releasing vitamin B12 analog, could selectively cross the blood-brain barrier and accumulate in glioblastoma tissue. They evaluated it using the NCI-60 human tumour cell line panel, pharmacokinetic studies in glioblastoma-bearing rats, and combination therapy experiments in human glioblastoma cell lines. Results showed that nitrosylcobalamin exhibited broad antitumour activity across multiple cancer types, while central nervous system tumour cell lines showed intermediate sensitivity. In animal experiments, nitrosylcobalamin successfully crossed the blood-brain barrier and preferentially accumulated within glioblastoma tissue after systemic administration. Tumour nitrate levels remained elevated 24 hours after treatment, while levels in normal tissues declined more rapidly, supporting selective tumour retention and localised nitric oxide delivery within the tumour microenvironment. The compound also demonstrated strong synergistic effects when combined with existing therapies. In cultured U87 and D54 glioblastoma cells, combining nitrosylcobalamin with both TRAIL and temozolomide produced substantially greater suppression of tumour cell proliferation than either treatment alone, with combination index analysis confirming synergistic interactions across multiple dose ranges. Researchers noted that nitrosylcobalamin may also help overcome resistance mechanisms by triggering apoptosis through caspase-8 activation, inhibiting NF-kB survival signaling, and enhancing TRAIL receptor signaling through S-nitrosylation. “This pilot study demonstrates that NO-Cbl crosses the blood-brain barrier, accumulates selectively in brain tumour tissue, and synergises with established and experimental glioblastoma therapies,” the authors wrote. The authors stress that this represents a pilot translational study, and additional research is needed before clinical application. Future investigations will focus on orthotopic validation, dose optimisation, longitudinal nitric oxide tracking, and further mechanistic studies in central nervous system tumour models. The findings contribute to growing interest in repurposing and modifying natural compounds like vitamin B12 for oncology. By leveraging the natural uptake mechanisms of vitamin B12, nitrosylcobalamin appears to exploit biological differences between tumour and healthy tissue for more precise drug delivery, an approach that may help address longstanding challenges in treating brain cancer.